Clinical Trial Detail

NCT ID NCT04126070
Title Nivolumab + Docetaxel + ADT in Metastatic Hormone Sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Xiao X. Wei
Indications

prostate adenocarcinoma

Therapies

Docetaxel + Nivolumab

Leuprolide

Goserelin

Degarelix

Age Groups: senior adult

No variant requirements are available.